Renaissance Group LLC Raises Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Renaissance Group LLC lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 42.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,572 shares of the company's stock after purchasing an additional 29,696 shares during the period. Renaissance Group LLC owned about 0.21% of Amphastar Pharmaceuticals worth $3,697,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust increased its holdings in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares during the period. Huntington National Bank raised its position in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after purchasing an additional 361 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after buying an additional 388 shares during the period. Finally, KBC Group NV grew its position in shares of Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after buying an additional 650 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

AMPH has been the topic of a number of recent analyst reports. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday.

Amphastar Pharmaceuticals Trading Up 1.1 %

Shares of AMPH stock traded up $0.26 during trading hours on Monday, hitting $24.42. 113,639 shares of the company were exchanged, compared to its average volume of 455,798. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.74 and a fifty-two week high of $53.96. The company has a 50 day simple moving average of $28.68 and a two-hundred day simple moving average of $38.07. The firm has a market cap of $1.16 billion, a P/E ratio of 8.14, a P/E/G ratio of 2.19 and a beta of 0.79.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 27.10% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.